Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001304 | 0.77 | ALDH1A1 (0.56) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL12232628 | 0.77 | PDE3B (0.54) | ALDH1A1PDE3BPDE3A | |
| SCHEMBL8781282 | 0.69 | ALDH1A1 (0.51) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL11478869 | 0.68 | ALDH1A1 (0.60) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL23706120 | 0.68 | PSMB8 (0.46) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL30097028 | 0.68 | PSMB8 (0.46) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL8781343 | 0.68 | PSMB8 (0.46) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL11335850 | 0.67 | MAPT (0.48) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL777616 | 0.65 | PSMB8 (0.50) | PSMB8KDM4EALDH1A1GAACCR1 | |
| SCHEMBL18282199 | 0.64 | PSMB8 (0.41) | PSMB8KDM4EALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20140113824-A1 | BICYCLIC (THIO)CARBONYLAMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2707373-A1 | BICYCLIC (THIO)CARBONYLAMIDINES | Bayer Intellectual Property GmbH (DE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152741-A1 | BICYCLIC (THIO)CARBONYLAMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | PSMB8 444/4885KDM4E 418/4885ALDH1A1 2879/4885 |
| US-20140113824-A1 | BICYCLIC (THIO)CARBONYLAMIDINES | BROX, BOLA2; BOLA2B, CAT | PSMB8 1558/4885KDM4E 1905/4885ALDH1A1 1780/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | PSMB8 389/4885KDM4E 383/4885ALDH1A1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.